Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3)

What Was Tested

The paper reports a study of Insulin Aspart and Insulin Detemir, published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Primary endpoint was HbA1c change from baseline after 18 weeks of treatment.

Secondary endpoints included: postprandial plasma glucose (PPG) change and overall PPG increment (all meals); weight; treatment-emergent adverse events; hypoglycaemic episodes.

How the Study Was Run

The design is described as randomized and open-label.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Insulin Aspart study did not mask who received what.

A time span of 18 weeks appears in the methods.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Insulin Aspart and Insulin Detemir.

The authors tagged it with the keywords glycaemic control, hypoglycaemia, insulin therapy, phase 3 study, randomized trial and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized and open-label study of Insulin Aspart and Insulin Detemir over 18 weeks.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Insulin Aspart compound page and the Insulin Detemir compound page.